Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

Summary

This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.

Timeline

Start

2024-10-01

Primary completion

2026-10-01

Completion

2028-10-01

Drugs

Indications